kwic
increased
increased
right
off
ON
19
1
100
500
strict
ELIZA cgi-bash version rev. 1.91
- Medical English LInking keywords finder for the PubMed Zipped Archive (ELIZA) -
return
kwic search for increased out of >500 occurrences
611425 occurrences (No.13 in the rank) during 5 years in the PubMed. [cache]
--- ABSTRACT ---
--- ABSTRACT END ---
[frequency of next (right) word to increased]
611425 occurrences (No.13 in the rank) during 5 years in the PubMed. [cache]
| 19) However, biologics are costly, and can cause side effects, such as an increased risk of infection. |
| PMID:33453052 DOI:10.1007/s40265-020-01448-z |
| 2021 Drugs |
| * Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review. |
| - Biologics are effective in treating psoriasis amongst other diseases, such as rheumatoid arthritis and Crohn’s disease. However, biologics are costly, and can cause side effects, such as an increased risk of infection. In patients with rheumatoid arthritis, it is not uncommon to lower the dose of these biologics (also called “dose tapering”), once stable low disease activity, or even remission, is reached. However, in psoriasis patients, dose tapering of biologics is not common practice. In this “scoping review,” we provide an overview of the available literature on dose tapering of biologics in adult patients with plaque psoriasis in order to address the current gaps in literature. We found 19 studies that addressed dose tapering. These studies used different criteria to determine which patients were eligible for tapering, which led to various interpretations of tapering success. This made it difficult for us to draw general conclusions on which tapering criteria and strategies should be further investigated. Dose tapering seems to be effective and safe in patients with a stable low disease activity, although more (high-quality) research is needed. Future studies should focus on generating more data on long-term safety, finding predictors for successful tapering, calculating the cost-effectiveness of dose tapering, and evaluating dose tapering in the newest generation of biologics. |
[
right
kwic]
(1)32  risk |
(13)3 focus |
(26)2 after |
(38)2 intracranial |
| (2)19 the |
(14)3 for |
(27)2 and |
(39)2 lifespan |
| (3)14 in |
(15)3 incidence |
(28)2 appetite, |
(40)2 mental |
| (4)6 awareness |
(16)3 sensitivity |
(29)2 approximately |
(41)2 mortality |
| (5)6 levels |
(17)3 signal |
(30)2 body |
(42)2 patients' |
| (6)6 over |
(18)3 significantly |
(31)2 by |
(43)2 placental |
| (7)5 *null* | (19)3 survival |
(32)2 cell |
(44)2 rate |
| (8)5 or |
(20)3 time |
(33)2 demands |
(45)2 research |
| (9)5 use |
(21)3 to |
(34)2 depressive |
(46)2 retropalatal |
| (10)4 serum |
(22)3 vaccine |
(35)2 detection |
(47)2 severity |
| (11)3 during |
(23)2 CYP2B6 |
(36)2 exposure |
(48)2 uptake |
| (12)3 expression |
(24)2 DNA |
(37)2 from |
(49)2 virus |
add keyword
--- WordNet output for increased ---